DK3094322T3 - Administration af tasimelteon i fastende tilstand - Google Patents

Administration af tasimelteon i fastende tilstand Download PDF

Info

Publication number: DK3094322T3
Authority: DK; Denmark
Prior art keywords: tasimelteon; administration; fixed mode; mode; fixed
Prior art date: 2014-01-14

Application number

DK15701861.5T

Other languages

English (en)

Inventor

Marlene Michelle Dressman

Mihael H Polymeropoulos

Paolo Baroldi

Original Assignee

Vanda Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-01-14

Filing date

2015-01-07

Publication date

2020-07-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53520399&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3094322(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-01-07 Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc

2020-07-20 Application granted granted Critical

2020-07-20 Publication of DK3094322T3 publication Critical patent/DK3094322T3/da

Links

PTOIAAWZLUQTIO-GXFFZTMASA-N tasimelteon Chemical compound CCC(=O)NC[C@@H]1C[C@H]1C1=CC=CC2=C1CCO2 PTOIAAWZLUQTIO-GXFFZTMASA-N 0.000 title 1
229960000660 tasimelteon Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Anesthesiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

DK15701861.5T 2014-01-14 2015-01-07 Administration af tasimelteon i fastende tilstand DK3094322T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201461927465P	2014-01-14	2014-01-14
US14/511,669 US10376487B2 (en)	2013-11-12	2014-10-10	Method of treatment
PCT/US2015/010410 WO2015108728A1 (en)	2014-01-14	2015-01-07	Administration of tasimelteon under fasted conditions

Publications (1)

Publication Number	Publication Date
DK3094322T3 true DK3094322T3 (da)	2020-07-20

Family

ID=53520399

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK15701861.5T DK3094322T3 (da)	2014-01-14	2015-01-07	Administration af tasimelteon i fastende tilstand

Country Status (19)

Country	Link
US (4)	US10376487B2 (da)
EP (1)	EP3094322B1 (da)
JP (4)	JP2017502996A (da)
KR (3)	KR102276569B1 (da)
CN (2)	CN107072978A (da)
AU (3)	AU2015206797A1 (da)
CA (2)	CA2936504C (da)
CL (1)	CL2016001794A1 (da)
DK (1)	DK3094322T3 (da)
ES (1)	ES2805451T3 (da)
HR (1)	HRP20201069T1 (da)
HU (1)	HUE051244T2 (da)
IL (1)	IL246676B (da)
MX (1)	MX377438B (da)
NZ (1)	NZ722254A (da)
PT (1)	PT3094322T (da)
SI (1)	SI3094322T1 (da)
WO (1)	WO2015108728A1 (da)
ZA (1)	ZA201605103B (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT2028937E (pt) *	2006-05-22	2015-04-09	Vanda Pharmaceuticals Inc	Tratamento por agonista de melatonina
CA3085116C (en)	2012-01-26	2022-07-19	Vanda Pharmaceuticals Inc.	Treatment of circadian rhythm disorders
US11918557B2 (en)	2012-01-26	2024-03-05	Vanda Pharmaceuticals Inc.	Treatment of circadian rhythm disorders
US10376487B2 (en)	2013-11-12	2019-08-13	Vanda Pharmaceuticals Inc.	Method of treatment
US11090285B2 (en)	2013-11-12	2021-08-17	Vanda Pharmaceuticals Inc	Treatment of circadian rhythm disorders
AU2015312252B2 (en) *	2014-09-02	2020-07-02	Vanda Pharmaceuticals Inc.	Tasimelteon for treating Smith-Magenis Syndrome
WO2019028245A1 (en)	2017-08-02	2019-02-07	Vanda Pharmaceuticals Inc.	USE OF TASIMELTÉON FOR THE TREATMENT OF AFFECTIVE DISORDERS
US20210353586A1 (en) *	2018-09-12	2021-11-18	Vanda Pharmaceuticals Inc.	Improving Sleep or Post-Sleep Performance
EP4072542A1 (en)	2019-12-13	2022-10-19	Vanda Pharmaceuticals Inc.	Liquid tasimelteon formulations and methods of use thereof
EP4401723A1 (en)	2021-09-14	2024-07-24	Vanda Pharmaceuticals Inc.	Treatment of sleep disturbances in autism spectrum disorder patients

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL50699A0 (en)	1975-10-28	1976-12-31	Ici America Inc	Triazole derivatives
DE3466215D1 (en)	1983-05-18	1987-10-22	Univ Monash	The use of melatonin for the manufacture of a medicament
IL79264A0 (en)	1986-06-27	1986-09-30	Univ Ramot	Tryptamine derivatives,pharmaceutical compositions containing them and their use in an assay for melatonin receptors
US4997845A (en)	1987-02-02	1991-03-05	Eli Lilly And Company	β-alkylmelatonins as ovulation inhibitors
US5093352A (en)	1988-11-14	1992-03-03	Whitby Research, Inc.	Antidepressant agents
US5151446A (en)	1989-09-25	1992-09-29	Northwestern University	Substituted 2-amidotetralins as melatonin agonists and antagonists
FR2658818B1 (fr)	1990-02-27	1993-12-31	Adir Cie	Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5242941A (en)	1990-12-04	1993-09-07	State Of Oregon	Methods of treating circadian rhythm disorders
US6638963B1 (en)	1990-12-04	2003-10-28	Oregon Health And Science University	Methods for treating circadian rhythm disorders
IT1251544B (it)	1991-05-13	1995-05-17	Gabriele Biella	Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
US6180657B1 (en)	1993-11-18	2001-01-30	Eli Lilly And Company	Melatonin derivatives for use in treating desynchronization disorders
US5403851A (en)	1994-04-05	1995-04-04	Interneuron Pharmaceuticals, Inc.	Substituted tryptamines, phenalkylamines and related compounds
GB9416884D0 (en)	1994-08-20	1994-10-12	Danbiosyst Uk	Drug delivery compositions
WO1996023496A1 (en)	1995-02-01	1996-08-08	Neurim Pharmaceuticals (1991) Ltd.	Use of melatonin for treating patients suffering from drug addiction
US5932541A (en)	1995-10-24	1999-08-03	Gruenenthal Gmbh	Method of adjusting the circadian rhythm of a mammal
RU2190609C2 (ru)	1996-12-10	2002-10-10	Бристол-Маерс Сквибб Компани	Производные бензодиоксола, бензофурана, дигидробензофурана и бензодиоксана и содержащие их композиции
US5776969A (en)	1997-02-27	1998-07-07	Eli Lilly And Company	Treatment of sleep disorders
AUPO588297A0 (en)	1997-03-26	1997-04-24	Luminis Pty Limited	Mediation in melatonin production
DE69910795T2 (de)	1998-06-09	2004-06-17	Takeda Chemical Industries, Ltd.	Pharmazeutische kombination mit einer trizyclischen verbindung und mindestens einer von zolpidem, zopiclone und brotizolam, zur behandlung oder verhinderung von schlafstörungen
US6562858B2 (en)	1999-05-17	2003-05-13	St. Elizabeth's Medical Center Of Boston, Inc.	Method for treating depression
ES2213022T3 (es)	1999-06-30	2004-08-16	Bristol-Myers Squibb Company	Derivados de aminopirrolidina heterociclicos utiles como agentes melatonergicos.
ES2358416T3 (es)	2001-10-30	2011-05-10	Novartis Ag	Formulaciones de liberación prolongada de iloperidona y polímero en forma de estrella.
GB0216416D0 (en)	2002-07-15	2002-08-21	Novartis Ag	Organic compounds
IL155666A (en)	2003-04-29	2013-12-31	Neurim Pharma 1991	Insomnia treatment
JP2005080603A (ja)	2003-09-10	2005-03-31	Kumamoto Technology & Industry Foundation	生体リズム障害の度合の判断方法
US20050137247A1 (en)	2003-12-22	2005-06-23	The Brigham And Women's Hospital, Inc.	Methods and compositions for treatment of hypertension
EP1696959A2 (en)	2003-12-24	2006-09-06	Sepracor, Inc.	Melatonin combination therapy for improving sleep quality
AU2006275824B2 (en)	2005-07-29	2010-12-16	Vanda Pharmaceuticals, Inc.	Method of improving wakefulness
US7754902B2 (en)	2006-05-18	2010-07-13	Vanda Pharmaceuticals, Inc.	Ruthenium(II) catalysts for use in stereoselective cyclopropanations
PT2028937E (pt)	2006-05-22	2015-04-09	Vanda Pharmaceuticals Inc	Tratamento por agonista de melatonina
AU2007253704A1 (en)	2006-05-22	2007-11-29	Vanda Pharmaceuticals, Inc.	Treatment for depressive disorders
WO2008011150A1 (en)	2006-07-20	2008-01-24	Somaxon Pharmaceuticals, Inc.	Methods of improving the pharmacokinetics of doxepin
WO2008011120A2 (en)	2006-07-21	2008-01-24	The Regents Of The University Of California	Human endogenous retrovirus polypeptide compositions and methods of use thereof
WO2008070795A2 (en)	2006-12-06	2008-06-12	Somaxon Pharmaceuticals, Inc.	Combination therapy using low-dose doxepin for the improvement of sleep
SI3461503T1 (sl)	2007-04-11	2022-04-29	Biomarin Pharmaceutical Inc.	Postopki za dajanje tetrahidrobiopterina, povezani sestavki in postopki merjenja
EP2195462B1 (en)	2007-09-13	2013-06-12	Vanda Pharmaceuticals Inc.	Prediction of sleep parameter and response to sleep-inducing compound based on per3 vntr genotype
WO2009084023A2 (en)	2007-10-19	2009-07-09	Glenmark Generics Limited	Amorphous ramelteon and process for the preparation thereof
EP2215073A4 (en)	2007-10-31	2011-04-06	Merck Sharp & Dohme	SLEEP MODULATION WITH NR2B RECEPTOR ANTAGONISTS
JP5558016B2 (ja)	2009-03-17	2014-07-23	株式会社資生堂	概日リズム調整剤
US20120183610A1 (en)	2009-04-07	2012-07-19	Lennernaes Hans	glucocorticoid therapy
US20120136050A1 (en)	2009-07-16	2012-05-31	Vanda Pharmaceuticals Inc.	Use of a melatonin agonist for the treatment of sleep disorders including primary insomnia
CA3085116C (en)	2012-01-26	2022-07-19	Vanda Pharmaceuticals Inc.	Treatment of circadian rhythm disorders
US10376487B2 (en)	2013-11-12	2019-08-13	Vanda Pharmaceuticals Inc.	Method of treatment
EP3105212A1 (en)	2014-02-12	2016-12-21	Vanda Pharmaceuticals Inc.	Highly purified pharmaceutical grade tasimelteon

2014
- 2014-10-10 US US14/511,669 patent/US10376487B2/en active Active
2015
- 2015-01-07 JP JP2016546950A patent/JP2017502996A/ja active Pending
- 2015-01-07 WO PCT/US2015/010410 patent/WO2015108728A1/en not_active Ceased
- 2015-01-07 CN CN201580004542.9A patent/CN107072978A/zh active Pending
- 2015-01-07 KR KR1020207025212A patent/KR102276569B1/ko active Active
- 2015-01-07 CN CN202211546550.4A patent/CN116115551A/zh active Pending
- 2015-01-07 EP EP15701861.5A patent/EP3094322B1/en active Active
- 2015-01-07 KR KR1020167021922A patent/KR101970050B1/ko active Active
- 2015-01-07 AU AU2015206797A patent/AU2015206797A1/en not_active Abandoned
- 2015-01-07 CA CA2936504A patent/CA2936504C/en active Active
- 2015-01-07 SI SI201531280T patent/SI3094322T1/sl unknown
- 2015-01-07 NZ NZ722254A patent/NZ722254A/en unknown
- 2015-01-07 DK DK15701861.5T patent/DK3094322T3/da active
- 2015-01-07 KR KR1020197010189A patent/KR102154458B1/ko active Active
- 2015-01-07 ES ES15701861T patent/ES2805451T3/es active Active
- 2015-01-07 HU HUE15701861A patent/HUE051244T2/hu unknown
- 2015-01-07 MX MX2016009231A patent/MX377438B/es active IP Right Grant
- 2015-01-07 PT PT157018615T patent/PT3094322T/pt unknown
- 2015-01-07 HR HRP20201069TT patent/HRP20201069T1/hr unknown
- 2015-01-07 CA CA3091827A patent/CA3091827A1/en not_active Abandoned
2016
- 2016-07-10 IL IL246676A patent/IL246676B/en active IP Right Grant
- 2016-07-13 CL CL2016001794A patent/CL2016001794A1/es unknown
- 2016-07-21 ZA ZA2016/05103A patent/ZA201605103B/en unknown
2019
- 2019-07-19 US US16/517,111 patent/US10610511B2/en active Active
2020
- 2020-02-25 US US16/800,611 patent/US11141400B2/en active Active
- 2020-04-23 AU AU2020202719A patent/AU2020202719B2/en active Active
2021
- 2021-03-22 JP JP2021047935A patent/JP2021102634A/ja active Pending
- 2021-08-20 US US17/407,921 patent/US11786502B2/en active Active
2022
- 2022-03-21 AU AU2022201953A patent/AU2022201953A1/en not_active Abandoned
- 2022-12-23 JP JP2022206745A patent/JP2023024704A/ja active Pending
2025
- 2025-07-24 JP JP2025124086A patent/JP2025137763A/ja active Pending

Also Published As

Publication number	Publication date
WO2015108728A1 (en)	2015-07-23
JP2025137763A (ja)	2025-09-19
KR101970050B1 (ko)	2019-04-17
HUE051244T2 (hu)	2021-03-01
US10376487B2 (en)	2019-08-13
US20190336470A1 (en)	2019-11-07
CL2016001794A1 (es)	2017-04-28
JP2023024704A (ja)	2023-02-16
RU2016133348A (ru)	2018-02-20
US10610511B2 (en)	2020-04-07
ZA201605103B (en)	2023-07-26
JP2017502996A (ja)	2017-01-26
IL246676A0 (en)	2016-08-31
KR102154458B1 (ko)	2020-09-09
US20210379008A1 (en)	2021-12-09
US20150196527A1 (en)	2015-07-16
JP2021102634A (ja)	2021-07-15
EP3094322B1 (en)	2020-04-08
US11786502B2 (en)	2023-10-17
KR20160106735A (ko)	2016-09-12
SI3094322T1 (sl)	2020-08-31
US20170087122A9 (en)	2017-03-30
AU2020202719B2 (en)	2022-03-10
AU2015206797A1 (en)	2016-08-04
HK1231404A1 (zh)	2017-12-22
ES2805451T3 (es)	2021-02-12
HRP20201069T1 (hr)	2020-10-30
KR102276569B1 (ko)	2021-07-12
MX377438B (es)	2025-03-10
MX2016009231A (es)	2016-10-05
KR20200106094A (ko)	2020-09-10
CA2936504A1 (en)	2015-07-23
PT3094322T (pt)	2020-07-14
NZ722254A (en)	2022-07-01
EP3094322A1 (en)	2016-11-23
CA3091827A1 (en)	2015-07-23
CN116115551A (zh)	2023-05-16
US20200188346A1 (en)	2020-06-18
US11141400B2 (en)	2021-10-12
KR20190040102A (ko)	2019-04-16
CN107072978A (zh)	2017-08-18
CA2936504C (en)	2020-10-13
AU2022201953A1 (en)	2022-04-14
IL246676B (en)	2020-10-29
AU2020202719A1 (en)	2020-05-14
RU2016133348A3 (da)	2018-09-26

Publication	Publication Date	Title
DK3137169T3 (da)	2022-02-14	Hæmmere af lysin-specifik demethylase-1
DK3132034T3 (da)	2020-10-19	Terapeutikum
DK3851537T5 (da)	2024-08-19	Behandling af hyperbilirubinæmi
DK3220989T3 (da)	2020-08-24	Intranasal administration
DK3148625T3 (da)	2023-07-31	Opklappelig kateterpakning
DK3174483T3 (da)	2022-01-03	Hyporørkonstruktion
DK3164123T3 (da)	2020-08-03	Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier
DK3236960T3 (da)	2025-03-31	Fluralaner til anvendelse i behandling af demodicose
DK3418273T3 (da)	2022-03-21	Derivater af flavagliner
PL3207149T3 (pl)	2023-08-21	Kompozycja farmaceutyczna o zwiększonej stabilności
DK3297619T3 (da)	2022-08-15	Terapeutiske anvendelser af L-4-chlorkynurenin
DK3173071T3 (da)	2021-06-28	Formularing af maropitant
DK2944309T3 (da)	2019-06-03	Anvendelse af palmitoylethanolamid i kombination med opioider
DK3018383T3 (da)	2019-06-11	Afslutning af styrkeelementer i dybhavskabler
DK3148513T3 (da)	2020-05-25	Ceritinib-formulering
DK3155422T3 (da)	2019-07-15	Demaskering af endotoxiner i opløsning
HUE047581T2 (hu)	2020-05-28	Készítmény
DK3200783T3 (da)	2019-08-05	Behandling af erytromelalgi
DK3193856T3 (da)	2021-09-06	Formulering
ME03083B (me)	2019-01-20	Veštački sfinkter
FR3019552B1 (fr)	2016-04-01	Composition filmogene
DK3154942T3 (da)	2019-11-18	Fremstilling af piperidin-4-carbothioamid
DK3104839T3 (da)	2020-01-20	Topiske formuleringer af heparin
HRP20190314T1 (hr)	2019-05-03	Set za špricu
DK3417873T3 (da)	2020-01-27	Ultrarene hypoallergene opløsninger af sacrosidase